Sanofi Pasteur releases FluQuadri vaccine
Sanofi Pasteur, the vaccine division of Sanofi, recently announced the launch of its 4-strain influenza vaccine FluQuadri in India. FluQuadri will be India’s first quadrivalent vaccine to provide broader protection against influenza to population above 3 years of age. Currently, the majority of seasonal influenza vaccines are trivalent, meaning that they protect against: two A strains and one single B lineage (B/Victoria or B/Yamagata) of Influenza virus. However, over the recent flu seasons, co-circulation of both B lineages has been consistently observed, making it difficult for the World Health Organization (WHO) to recommend which B strain should be incorporated in trivalent influenza vaccines. Given the change in epidemiology, quadrivalent vaccination represent the next logical step to an advanced level of protection. The WHO includes quadrivalent influenza vaccines in its recommendations, stating that Quadrivalent influenza vaccines that could potentially provide wider protection against influenza B viruses are becoming available and recommendations should not be limited to trivalent vaccine.